Global Lysosomal Storage Diseases Therapeutics 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08253333

Publication Date:

August 19, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Lysosomal storage disorders is a group of genetic metabolic diseases caused by enzyme deficiencies in various body cells.
The global Lysosomal Storage Diseases Therapeutics market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淟ysosomal Storage Diseases Therapeutics Industry Forecast鈥� looks at past sales and reviews total world Lysosomal Storage Diseases Therapeutics sales in 2023, providing a comprehensive analysis by region and market sector of projected Lysosomal Storage Diseases Therapeutics sales for 2024 through 2030. With Lysosomal Storage Diseases Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lysosomal Storage Diseases Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Lysosomal Storage Diseases Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lysosomal Storage Diseases Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Lysosomal Storage Diseases Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lysosomal Storage Diseases Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lysosomal Storage Diseases Therapeutics.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Lysosomal Storage Diseases Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by type
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Others
Segmentation by application
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
Pfizer
Sanofi
BioMarin Pharmaceutical
Actelion Ltd
Raptor Pharmaceutical
Protalix BiOthersapeutics
Amicus Therapeutics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Lysosomal Storage Diseases Therapeutics 麻豆原创 Size 2019-2030
2.1.2 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Lysosomal Storage Diseases Therapeutics Segment by Type
2.2.1 Enzyme Replacement Therapy
2.2.2 Stem Cell Therapy
2.2.3 Substrate Reduction Therapy
2.2.4 Others
2.3 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Type
2.3.1 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Lysosomal Storage Diseases Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Lysosomal Storage Diseases Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Application
2.5.1 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Lysosomal Storage Diseases Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Player
3.1 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Lysosomal Storage Diseases Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Lysosomal Storage Diseases Therapeutics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Lysosomal Storage Diseases Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Lysosomal Storage Diseases Therapeutics by Regions
4.1 Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Lysosomal Storage Diseases Therapeutics 麻豆原创 Size Growth (2019-2024)
4.3 APAC Lysosomal Storage Diseases Therapeutics 麻豆原创 Size Growth (2019-2024)
4.4 Europe Lysosomal Storage Diseases Therapeutics 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Lysosomal Storage Diseases Therapeutics 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Country (2019-2024)
5.2 Americas Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Type (2019-2024)
5.3 Americas Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Region (2019-2024)
6.2 APAC Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Type (2019-2024)
6.3 APAC Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Lysosomal Storage Diseases Therapeutics by Country (2019-2024)
7.2 Europe Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Type (2019-2024)
7.3 Europe Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lysosomal Storage Diseases Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Lysosomal Storage Diseases Therapeutics 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.1 Global Lysosomal Storage Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Lysosomal Storage Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Lysosomal Storage Diseases Therapeutics Forecast
10.1.3 APAC Lysosomal Storage Diseases Therapeutics Forecast
10.1.4 Europe Lysosomal Storage Diseases Therapeutics Forecast
10.1.5 Middle East & Africa Lysosomal Storage Diseases Therapeutics Forecast
10.2 Americas Lysosomal Storage Diseases Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.2.2 Canada Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.2.3 Mexico Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.2.4 Brazil Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3 APAC Lysosomal Storage Diseases Therapeutics Forecast by Region (2025-2030)
10.3.1 China Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3.2 Japan Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3.3 Korea Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3.4 Southeast Asia Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3.5 India Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.3.6 Australia Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.4 Europe Lysosomal Storage Diseases Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.4.2 France Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.4.3 UK Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.4.4 Italy Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.4.5 Russia Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.5 Middle East & Africa Lysosomal Storage Diseases Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.5.2 South Africa Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.5.3 Israel Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.5.4 Turkey Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.5.5 GCC Countries Lysosomal Storage Diseases Therapeutics 麻豆原创 Forecast
10.6 Global Lysosomal Storage Diseases Therapeutics Forecast by Type (2025-2030)
10.7 Global Lysosomal Storage Diseases Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Lysosomal Storage Diseases Therapeutics Product Offered
11.1.3 Takeda Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Takeda Main Business Overview
11.1.5 Takeda Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Lysosomal Storage Diseases Therapeutics Product Offered
11.2.3 Pfizer Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Lysosomal Storage Diseases Therapeutics Product Offered
11.3.3 Sanofi Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 BioMarin Pharmaceutical
11.4.1 BioMarin Pharmaceutical Company Information
11.4.2 BioMarin Pharmaceutical Lysosomal Storage Diseases Therapeutics Product Offered
11.4.3 BioMarin Pharmaceutical Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 BioMarin Pharmaceutical Main Business Overview
11.4.5 BioMarin Pharmaceutical Latest Developments
11.5 Actelion Ltd
11.5.1 Actelion Ltd Company Information
11.5.2 Actelion Ltd Lysosomal Storage Diseases Therapeutics Product Offered
11.5.3 Actelion Ltd Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Actelion Ltd Main Business Overview
11.5.5 Actelion Ltd Latest Developments
11.6 Raptor Pharmaceutical
11.6.1 Raptor Pharmaceutical Company Information
11.6.2 Raptor Pharmaceutical Lysosomal Storage Diseases Therapeutics Product Offered
11.6.3 Raptor Pharmaceutical Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Raptor Pharmaceutical Main Business Overview
11.6.5 Raptor Pharmaceutical Latest Developments
11.7 Protalix BiOthersapeutics
11.7.1 Protalix BiOthersapeutics Company Information
11.7.2 Protalix BiOthersapeutics Lysosomal Storage Diseases Therapeutics Product Offered
11.7.3 Protalix BiOthersapeutics Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Protalix BiOthersapeutics Main Business Overview
11.7.5 Protalix BiOthersapeutics Latest Developments
11.8 Amicus Therapeutics
11.8.1 Amicus Therapeutics Company Information
11.8.2 Amicus Therapeutics Lysosomal Storage Diseases Therapeutics Product Offered
11.8.3 Amicus Therapeutics Lysosomal Storage Diseases Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Amicus Therapeutics Main Business Overview
11.8.5 Amicus Therapeutics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.